Bicara Therapeutics BCAX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -32.3%-1.5pp | -30.9%-4.2pp | -26.6%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 13.9×-0.7× | 14.6×+0.4× | 14.1×-11.7× | 25.8×+1.2× | 24.6×-3.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $8.46+15.3% | $7.34-0.5% | $7.38-7.5% | $7.98-5.3% | $8.43-71.2% | |
| Valuation | ||||||
| Market capitalization | $1.29B+39.8% | $921.98M+7.0% | $861.55M+66.1% | $518.64M-27.0% | $710.44M-25.1% | |
| Price / book | 2.5×+0.2× | 2.3×+0.2× | 2.1×+0.9× | 1.2×-0.4× | 1.5×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Bicara Therapeutics's ratios come from?
- Every ratio is computed from Bicara Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.